Healio

Once-monthly octreotide provides sustained acromegaly control with fewer injections

Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...
The Pharma Letter

Viatris racks up regulatory wins across therapy areas

US pharma Viatris (Nasdaq: VTRS) has logged four regulatory milestones across its global pipeline, spanning a US Food and ...
Nasdaq

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

Camurus AB: Camurus announces FDA acceptance of NDA resubmission for Oclaiz for the treatment of acromegaly

Oclaiz is a subcutaneous long-acting octreotid depot, designed for optimized disease control and convenient self-administration. The product is based on Camurus' FluidCrystal technology and is ...
Seeking Alpha

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today the launch of the first and only generic ...